25 completed, 10 active not recruiting, 8 recruiting, 4 terminated. 50 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 50 | Completed 25, Active not recruiting 10, Recruiting 8, Terminated 4, Withdrawn 2, Unknown 1 |
| Phase 1 | 2 | Completed 1, Terminated 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Lupron: new trials by email Literature Review of Lupron trials Research Report on Lupron
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial Abiraterone Acetate, Biospecimen Collection, Leuprolide Acetate - Recurrent Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 | Recruiting | Mayo Clinic | 202 | 2026-08-04 | 2026-09-18 |
| Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT Leuprolide, Degarelix, Relugolix - Prostate Cancer, Localized Prostate Carcinoma | Phase 2 | Recruiting | Baptist Health South Florida | 50 | 2026-07-29 | 2026-08-06 |
| Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer Darolutamide, Pembrolizumab, Lupron - Prostate Cancer, High-risk Prostate Cancer | Phase 2 | Recruiting | Icahn School of Medicine at Mount Sinai | 40 | 2026-05-21 | 2026-10-07 |
| Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response Testosterone cypionate, Luteinizing hormone-releasing hormone (LHRH) analogue, Darolutamide - Metastatic Castration-resistant Prostate Cancer | Phase 2 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 60 | 2026-03-09 | 2026-03-11 |
| The COSMYC Trial (COmbined Suppression of MYC) ZEN-3694, Testosterone cypionate, Enzalutamide - Metastatic Castration-resistant Prostate Cancer | Phase 2 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 50 | 2025-08-19 | 2026-10-30 |
| Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors Biospecimen Collection, Chest Radiography, Computed Tomography - Adult Ovarian Granulosa Cell Tumor | Phase 2 | Completed | National Cancer Institute (NCI) | 17 | 2024-02-08 | 2026-11-03 |
| Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer DFMO, testosterone cypionate, Luteinizing hormone-releasing hormone (LHRH) analogue - Prostate Cancer | Phase 2 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 50 | 2023-10-04 | 2026-01-14 |
| Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers Biopsy Procedure, Biospecimen Collection, Computed Tomography - Locally Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 20 | 2023-07-20 | 2026-11-16 |
| RElugolix VErsus LeUprolide Cardiac Trial Radiation therapy, Leuprolide, Relugolix - Biochemically Recurrent Prostate Carcinoma, Localized Prostate Carcinoma | Phase 2 | Active not recruiting | Emory University | 94 | 2022-06-06 | 2026-02-12 |
| Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer Abiraterone Acetate, Bicalutamide, Degarelix - Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 2 | Recruiting | City of Hope Medical Center | 70 | 2021-05-04 | 2026-01-28 |
| Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer Abiraterone Acetate, Apalutamide, Leuprolide Acetate - Metastatic Prostate Adenocarcinoma, Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation | Phase 2 | Active not recruiting | Jonsson Comprehensive Cancer Center | 28 | 2021-03-17 | 2026-02-05 |
| Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study Apalutamide, Degarelix, Leuprolide Acetate - Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2020-11-24 | 2021-01-20 | |
| Bariatric Arterial Embolization for Men Starting Hormones for Prostate Cancer Bead Block 300-500 um, Weight Management, Lupron - Prostate Adenocarcinoma, Obesity, Morbid | Phase 2 | Withdrawn | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2020-11-16 | 2022-05-02 | |
| Characterizing the Neural Substrates of Irritability in Women: an Experimental Neuroendocrine Model Leuprolide Acetate 3.75 MG/ML, Estradiol 2 Mg tablet, Micronized progesterone - Perinatal Depression, Post Partum Depression | Phase 2 | Completed | University of North Carolina, Chapel Hill | 23 | 2020-01-02 | 2023-08-25 |
| REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer REGN2810, Degarelix, Leuprolide Acetate - Prostate Cancer Metastatic | Phase 2 | Active not recruiting | Mark Stein | 26 | 2019-05-16 | 2025-04-25 |
| Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer Leuprolide Acetate, Goserelin Acetate, Stereotactic Body Radiation Therapy - Prostate Adenocarcinoma | Phase 2 | Active not recruiting | City of Hope Medical Center | 25 | 2018-08-29 | 2026-04-09 |
| A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment 5-Azacitidine, all trans retinoic acid, Lupron - Prostatic Neoplasms, Prostate Neoplasms | Phase 2 | Completed | Icahn School of Medicine at Mount Sinai | 14 | 2018-08-20 | 2024-04-30 |
| Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery HSV-Tk, Valacyclovir, Bicalutamide - High-risk Prostate Cancer, Prostate Cancer | Phase 2 | Recruiting | The Methodist Hospital Research Institute | 60 | 2018-08-02 | 2021-04-06 |
| Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy Apalutamide, Leuprolide, Prednisone - Prostate Cancer | Phase 2 | Completed | Dana-Farber Cancer Institute | 118 | 2016-10-19 | 2025-06-13 |
| Apalutamide and Leuprolide in Intermediate and High-risk Prostate Cancer Leuprolide acetate, Apalutamide, Radical prostatectomy - Prostate Cancer | Phase 2 | Completed | Case Comprehensive Cancer Center | 54 | 2016-10-17 | 2022-06-21 |
Showing 20 of 50. Sign in to see all of them.
Prostatic Neoplasms (33) · Breast Neoplasms (2) · Depression, Postpartum (2) · Lymphoma, Non-Hodgkin (2) · Multiple Myeloma (2) · Myelodysplastic Syndromes (2) · Neoplasms (2) · Depression (1) · Eye Neoplasms (1) · Granulosa cell tumor of the ovary (1) · Hodgkin Disease (1) · Insulin Resistance (1) · Leukemia (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Acute (1)
National Cancer Institute (NCI) (7) · M.D. Anderson Cancer Center (5) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (4) · City of Hope Medical Center (3) · Mayo Clinic (3) · University of Washington (3) · Dana-Farber Cancer Institute (2) · Icahn School of Medicine at Mount Sinai (2) · Memorial Sloan Kettering Cancer Center (2) · Abbott (1) · Baptist Health South Florida (1) · Barbara Ann Karmanos Cancer Institute (1) · Case Comprehensive Cancer Center (1) · Emory University (1) · Jonsson Comprehensive Cancer Center (1)
United States (48) · Canada (2) · Czechia (1)
Celestia Higano, MD (2) · Christopher Logothetis (2) · Samuel Denmeade, MD (2) · Alan L Ho (1) · Amado Zurita, MD (1) · Amar Kishan (1) · Ann Partridge, MD (1) · Anne R. Cappola, MD, ScM (1) · Ashutosh K Tewari, MD (1) · Catherine Marshall, M.D. (1) · Christopher G Kanakry, M.D. (1) · Crystal E Schiller, PhD (1) · Cy A Stein (1) · Dimple Chakravarty, PhD (1) · Douglas McNeel, MD (1)
PMID 19012911, PMID 20818327, PMID 22006050, PMID 25242417, PMID 25847934, PMID 29248669, PMID 33496795, PMID 33683939, PMID 37922910, PMID 38161319, PMID 38494380, PMID 39074346, PMID 39670843, PMID 40907514, PMID 41706486, PMID 42070324, PMID 42574969
P30CA015083 (2), P30CA033572 (2), K23AG019161 (1), N01CM00039 (1), N01CM62201 (1), N01CM62202 (1), N01CM62205 (1), N01CM62206 (1), P30CA008748 (1), P30CA015704 (1), P30CA016672 (1), P30CA022453 (1), P30CA138292 (1), P30DK019525 (1), P50CA272391 (1)